Transforming growth factor-b (TGF-b) is an important cytokine in the fibrogenesis in many organs, including the pancreas. Using an adenoviral vector expressing the entire extracellular domain of type II human TGF-b receptor (AdTb-ExR), we investigated whether inhibition of TGF-b action is effective against persistent pancreatic fibrosis, and whether it exerts a beneficial effect on the pancreas in the process of chronic injury. To induce chronic pancreatic injury and pancreatic fibrosis, mice were subjected to three episodes of acute pancreatitis induced by six intraperitoneal injections of 50 lg/kg body weight cerulein at hourly intervals, per week for 3 consecutive weeks. Mice were infected once with AdTb-ExR, or with a control adenoviral vector expressing bacterial b-galactosidase (AdLacZ). Pancreatic fibrosis was evaluated by histology and hydroxyproline content. Activation of pancreatic stellate cells (PSCs) was assessed by immunostaining for a-smooth muscle actin. Apoptosis and proliferation of acinar cells were assessed by immunostaining of ssDNA and Ki-67, respectively. Three-week cerulein injection induced pancreatic fibrosis and pancreatic atrophy with proliferation of activated PSCs. In AdTb-ExR-injected mice, but not AdLacZ-injected mice, pancreatic fibrosis was significantly attenuated. This finding was accompanied by a reduction of activated PSCs. AdTb-ExR, but not AdLacZ, significantly increased pancreas weight after chronic pancreatic injury. AdTb-ExR did not change the proportion of proliferating acinar cells, whereas it reduced the number of apoptotic acinar cells. Our results demonstrate that inhibition of TGF-b action not only decreases pancreatic fibrosis but also protects the pancreas against chronic injury by preventing acinar cell apoptosis.
Identification of the molecular mechanisms involved in fibrosis of critical organs and the development of effective therapy are both clinically important. Transforming growth factor-b (TGF-b) is thought to regulate the production, degradation, and accumulation of extracellular matrix (ECM) proteins, and to play an important role in the fibroproliferative changes that follow tissue injury in many vital organs and tissues, including the heart, lung, kidney, and liver. [1] [2] [3] [4] [5] [6] [7] Chronic pancreatitis is an irreversible progressive disease characterized by destruction of exocrine parenchyma and its replacement with fibrosis. In fact, expression of TGF-b1 is enhanced in human chronic pancreatitis. [8] [9] [10] The importance of TGF-b signaling in the formation of fibrosis is underlined by experiments in transgenic mice overexpressing TGF-b1 in the pancreas. 11, 12 These animals show histological changes that resemble human chronic pancreatitis including destruction of the exocrine pancreas and progressive accumulation of ECM in the pancreas. These findings support the notion that TGF-b plays a pivotal role in pancreatic fibrosis. From a clinical point of view, understanding the in vivo effects of inhibition of TGF-b action is another approach to lead to the development of effective therapy. A previous study has demonstrated that inhibition of TGF-b1 by TGF-b1-neutralizing antibody reduces fibrotic responses in cerulein-induced acute pancreatitis. 13 However, it has long been a question whether inhibition of TGF-b is effective against persistent pancreatic fibrosis, and whether it exerts a beneficial effect on the pancreas in the process of chronic injury.
To address these questions, we constructed an adenoviral vector expressing the entire extracellular domain of the type II human TGF-b receptor fused to the Fc portion of human IgG (AdTb-ExR) and performed the present study. We have previously demonstrated that this soluble TGF-b receptor suppresses the action of TGF-b both in vitro and in vivo. 14, 15 This soluble receptor is secreted from cells infected with AdTb-ExR into the circulating blood, reaches remote area, binds to TGF-b, and thereby inhibits its action. [14] [15] [16] The use of AdTb-ExR can block the action of TGF-b in organs where direct gene transfer seems restrained. As an experimental pancreatic fibrosis model, we used mice treated with repeated cerulein injections, 17, 18 an established animal model of chronic pancreatic injury and pancreatic fibrosis with a pathophysiology that closely resembles that of human chronic pancreatitis.
Materials and methods

Replication-Defective Recombinant Adenoviruses
A replication-defective E1-and E3-adenoviral vector (AdTb-ExR) expressing the entire extracellular domain of the type II human TGF-b receptor fused to the Fc portion of human IgG, under the control of a CA promoter comprising a cytomegalovirus enhancer and a chicken b-actin promoter, was prepared as described previously. 14, 15 An adenoviral vector expressing bacterial b-galactosidase (AdLacZ) was used as a control adenoviral vector. The titer of the virus stock was assessed by a plaque formation assay using 293 cells and expressed in plaque-forming units (PFU). In previous studies, we showed that serum level of this soluble receptor reached a peak value at 5-7 days after the injection and gradually declined thereafter, but that it was still detectable even at 21 days after injection.
14-16
Animals
Male BALB/c mice (Kyudo Co., Kumamoto, Japan) weighing 20-22 g were used. The animals were kept in a 12 h light/dark cycle with free access to water and a standard mouse chow. The experiment was carried out under the guidelines of animal experiments of University of Occupational and Environmental Health, Japan, School of Medicine.
Experimental Protocol
Each mouse received an intraperitoneal injection of either AdTb-ExR (5 Â 10 8 PFU), AdLacZ (5 Â 10 8 PFU), or saline. Based on our previous studies using AdTb-ExR, we chose this viral dose (5 Â 10 8 PFU) as the optimal dose in this study. We have shown that this dose of AdTb-ExR adequately inhibits TGF-b action in remote organs without substantial toxicity in mice. 15 Three days after adenoviral injections, the mice were submitted to repeated acute pancreatitis episodes to induce chronic pancreatic injury and pancreatic fibrosis as described previously. 17, 18 Acute pancreatitis was elicited by hourly (6 times) intraperitoneal injections of 50 mg/kg body weight cerulein (Sigma-Aldrich, Tokyo, Japan), whereas control animals received a comparable amount of saline. Mice were submitted to three episodes of acute pancreatitis per week for 3 weeks. At the end of this period (3 days after final cerulein treatment), venous blood was collected and the mice were killed by administration of a lethal dose of pentobarbital. Pancreatic tissues were harvested, fixed in 4% paraformaldehyde buffered with 0.01 M sodium phosphate, pH 7.4 (PBS) overnight at 41C, and embedded in paraffin or frozen immediately in liquid nitrogen for extraction of hydroxyproline.
Histological Examination
Paraffin sections were stained with hematoxylineosin (H&E) and Azan-Mallory, or subjected to immunohistochemical staining using antibodies against collagen type I (LSL Co., Ltd., Tokyo), fibronectin (Dako Cytomation, Kyoto, Japan) a-smooth muscle actin (a-SMA) (Dako Cytomation), the proliferation marker Ki-67 antigen (Dako Cytomation), and single-stranded DNA (ssDNA) (Dako Cytomation), a specific and sensitive marker of apoptosis. [19] [20] [21] [22] Immunohistochemical staining of a-SMA was performed as described previously. 23 A DAKO EnVision system (Dako Cytomation) was used for collagen type I, fibronectin, and ssDNA immunostaining. Immunoreactivity of the Ki-67 antigen was visualized by the labeled streptavidinbiotin method (Dako Cytomation).
For quantitative analysis of apoptosis of acinar cells, the number of ssDNA-positive cells was determined under a high-power field ( Â 400 magnification, 10 random fields per section). Ki-67 labeling index (the portion of acinar cell nuclei that were Ki-67-positive) was expressed as a percentage of all acinar cells in the sections ( Â 400 magnification, 10 random fields per section). Five mice were analyzed for each group.
Quantitative Analysis of Pancreatic Fibrosis
A semiquantitative evaluation of fibrosis in the pancreatic specimen was performed using an Axiophot microscope (Carl Zeiss, Eching, Germany) connected to an IBAS image analysis system (Carl Zeiss) as described previously. 23 Five nonoverlapping fields per Azan-Mallory-stained Inhibiting TGF-b in chronic pancreatic injury Y Nagashio et al pancreatic specimen (n ¼ 5) were randomly selected at Â 20 magnification by an investigator who was unaware of the sample identity. The rate of pancreatic fibrosis was indicated as a percentage of total pancreatic specimen.
We also determined collagen contents in pancreatic tissue quantitatively by measuring pancreatic hydroxyproline content as described previously. 24 
Statistical Analysis
Data are expressed as means7s.e.m. Differences between groups were evaluated by one-way ANOVA. A P-value o0.05 was considered to be statistically significant.
Results
Repetitive Cerulein Injections Induce Pancreatic Fibrosis
Three-times weekly regimen of cerulein, induced acute pancreatitis followed by pancreatic fibrosis similar to that in human chronic pancreatitis. Although collagen deposition increased after 2 weeks of cerulein treatment, 17 we performed repetitive Inhibiting TGF-b in chronic pancreatic injury Y Nagashio et al intraperitoneal injections of cerulein for 3 weeks to induce fibrosis in the pancreas. In normal pancreas, collagen was observed around the pancreatic ducts and blood vessels (Figure 1a ). Cerulein injections induced massive collagen deposition in periacinar and interlobular areas with inflammatory infiltration and pancreatic atrophy (Figure 1b) . In addition, intra-acinar lumina became dilated and some acinar units appeared to redifferentiate into tubular complexes (Figure 1b) . Pancreatic stellate cells (PSCs) are known to mediate fibrogenesis in pancreas. [25] [26] [27] [28] [29] [30] When activated by profibrogenic mediators, PSCs transform into myofibroblast-like cells expressing a-SMA. In normal pancreas, a-SMA staining was seen mainly in blood vessel walls (Figure 1c) . On the other hand, cerulein injections induced the proliferation of a-SMA-positive activated PSCs in the fibrotic areas (Figure 1d ). These findings indicate that PSCs are responsible for pancreatic fibrosis in ceruleintreated mice and that this model is suitable for investigating fibrosis in the pancreas.
AdTb-ExR Attenuates Pancreatic Fibrosis
In AdLacZ-injected mice, intraperitoneal injections of cerulein induced tissue remodeling in the pancreas, with ECM protein deposition mainly in the periacinar and the interlobular areas, as shown by Azan staining (Figure 2a ) and immunostainings for collagen type I and fibronectin (Figure 2e and g ). The fibrotic area was also stained positively by an antibody against a-SMA (Figure 2a and c) . These histological changes were not significantly different from those of cerulein-treated mice injected with saline (data not shown). In contrast, AdTb-ExRinjected mice showed significant reduction of pancreatic fibrosis, as indicated by both Azan staining and immunostaining (Figure 2b, f, and h) . Moreover, AdTb-ExR reduced the a-SMA-positive area (Figure 2d vs c) .
Semiquantitative analysis of pancreatic fibrosis was performed by image analysis. Image analysis showed that the percentage of fibrotic area of AdTbExR-treated mice was markedly lower than in mice injected with either AdLacZ or saline (Figure 3a) . For quantitative comparison, we measured the hydroxyproline content in the pancreas. In cerulein-treated mice injected with either AdLacZ or saline, the amount of hydroxyproline was 5 times higher than that found in control mice (ie, mice not treated with cerulein) (Figure 3b ). In contrast, the hydroxyproline content in mice injected once with AdTb-ExR was significantly decreased (Figure 3b ).
Attenuation of Fibrosis by AdTb-ExR Reduces Loss of Pancreas Weight
A marked decrease in pancreas wet weight, which reflects pancreatic atrophy after chronic injury, was noted in cerulein-treated mice injected with either AdLacZ or saline, but this decrease was significantly attenuated in mice treated with AdTbExR (Figure 4 ).
An imbalance between apoptosis and proliferation in acinar cells is thought to be a possible mechanism involved in pancreatic exocrine cell loss of chronic pancreatitis. 31 We therefore assessed apoptosis and proliferation of acinar cells by immunostaining of ssDNA and Ki-67, respectively. The number of ssDNA-positive cells was increased in exocrine pancreas of cerulein-treated mice Inhibiting TGF-b in chronic pancreatic injury Y Nagashio et al injected with either AdLacZ or saline, whereas it was significantly decreased in mice treated with AdTb-ExR (Figure 5a-c) .
The Ki-67-positive acinar cells were rarely seen in control mouse pancreas (Figure 6a ), whereas they were increased in cerulein-and saline-treated (Figure 6b ) or cerulein-and AdLacZ-treated mice (Figure 6c ). Treatment with AdTb-ExR had no influence on the Ki-67 labeling index compared with that with AdLacZ (Figure 6d vs c, and Table 1 ).
Discussion
TGF-b is a major cytokine in the regulation of the production, degradation, and accumulation of ECM. Overexpression of TGF-b for a prolonged period of time after tissue damage induces a fibroproliferative response and deposition of ECM, resulting in fibrosis in vital organs. [2] [3] [4] [5] [6] [7] Many studies have demonstrated the presence of TGF-b1 in the form of either protein or message, in the fibrotic tissues of human chronic pancreatitis and animal models. [8] [9] [10] 23, 32 Van Laethem et al 33 demonstrated that repeated injections of recombinant TGF-b into mice after recurrent episodes of acute pancreatitis led to pancreatic fibrosis. On the other hand, Menke et al 13 have demonstrated that inhibition of TGF-b1 by TGF-b1-neutralizing antibody causes partial reduction of the accumulation of ECM (collagen type I and III, and fibronectin) during regeneration from the cerulein-induced acute pancreatitis. However, it has not been addressed in a persistent pancreatic fibrosis model whether inhibition of TGF-b action is effective in preventing fibrosis in the pancreas, and whether it exerts a beneficial effect on the pancreas in the process of chronic injury. The present study has answered all these questions by adenovirus-mediated expression of a soluble TGF-b receptor that can abolish TGF-b signaling. [14] [15] [16] It is now recognized that repeated episodes of acute pancreatitis can lead to increasing residual damage to the gland, eventually resulting in chronic pancreatitis (the necrosis-fibrosis sequence). 17, 34, 35 Therefore, we chose this chronic pancreatitis model induced by repeated acute pancreatitis in the present study. Although pancreatic fibrosis advanced in both AdLacZ-or saline-treated mice after a total of nine episodes of acute pancreatitis, the progression of fibrosis was greatly impeded in the Figure 4 Effect of AdTb-ExR on pancreas weight. Pancreas weight was determined in control, cerulein-treated, cerulein-and AdLacZ-treated, and cerulein-and AdTb-ExR-treated mice at the end of the 3-week study period, as described in Materials and methods. Pancreas weight was significantly increased in AdTbExR-injected mice. Data are mean7s.e.m. of 5 mice/group. AdTb-ExR-treated mice, as assessed by both histology ( Figure 2 ) and quantitation of hydroxyproline contents in the pancreas (Figure 3) . Moreover, the immunostaining analysis revealed that attenuation of pancreatic fibrosis by inhibition of TGF-b is accompanied by a reduction of activated PSCs. Accumulating evidence indicates that PSCs play a central role in the pathogenesis of pancreatic fibrosis. [25] [26] [27] [28] [29] [30] In response to pancreatic injury or inflammation, PSCs transform into myofibroblastlike phenotype expressing a-SMA, proliferate, and synthesize and secrete increased amounts of ECM proteins, particularly collagens and fibronectin. TGF-b plays key roles both in the activation of PSCs and in the stimulation of ECM protein synthesis. 26, 27, 29, 30 Moreover, previous studies strongly support the existence of autocrine and paracrine stimulatory loops of ECM protein synthesis in PSCs via TGF-b. [36] [37] [38] Thus, inhibition of TGF-b action may block these loops and thereby inhibit PSC activation and ECM protein deposition in the pancreas. However, the inhibitory effect of AdTb-ExR on pancreatic fibrosis was less impressive than that Another key finding in this study was that inhibition of TGF-b action significantly increased pancreas weight. ECM participates in the process of tissue repair after injury as well as in the development of fibrosis. Thus, one important question arises whether inhibition of ECM protein deposition through blockade of TGF-b action has beneficial effects on the pancreas in the process of chronic injury. In the present study, we found that inhibition of TGF-b action significantly protected pancreatic acinar cells from apoptosis. Previous studies demonstrated that apoptosis plays a significant role in acinar cell loss in chronic pancreatitis, 31 and that TGF-b induces apoptosis in a broad range of cell types. [39] [40] [41] Thus, inhibition of TGF-b action may attenuate pancreatic atrophy, in part by preventing acinar cell apoptosis. Since TGF-b1 has been demonstrated to be an inhibitor of pancreatic acinar cell growth in vitro, 42 it is conceivable that the increased pancreas weight by inhibiting TGF-b action might partially result from the enhanced proliferation of acinar cells. However, proliferation of acinar cells assessed by Ki-67 labeling index showed no significant differences between AdTbExR-and AdLacZ-treated mice. These differences can be explained by the differences in the experimental designs (ie, in vivo and in vitro). Under in vivo condition, a variety of factors besides TGF-b may regulate acinar cells proliferation in the process of chronic pancreatic injury. In fact, epidermal growth factor (EGF), fibroblast growth factor (FGF), and cholecystokinin (CCK) are known to regulate pancreatic acinar cell growth. [42] [43] [44] Considered together, these results suggest that inhibition of TGF-b action provides protection against chronic pancreatic injury by preventing acinar cell apoptosis.
In conclusion, our results demonstrate that inhibition of TGF-b action not only decreases pancreatic fibrosis but also protects the pancreas against chronic injury by preventing acinar cells apoptosis. Therefore, this study suggests that inhibition of TGF-b may be a potential therapeutical strategy for chronic pancreatitis. However, since elimination of the TGF-b signaling for a prolonged period might produce unfavorable consequences such as the inflammation and tissue necrosis as observed in TGF-b1 gene-disrupted mice, 45 we have to investigate carefully these issues in future studies.
